Form 4: Immix Biopharma CFO Gabriel Morris Increases Stake with Recent Stock Purchase

Immix Biopharma's CFO and Director, Gabriel S. Morris, reported the acquisition of 2,225 shares of common stock on June 18, 2025, increasing his direct and indirect beneficial ownership in the company.

Summary

• Gabriel S. Morris, who serves as both Chief Financial Officer and Director of Immix Biopharma, Inc. (IMMX), filed a Form 4 reporting a transaction on June 18, 2025.
• Mr. Morris acquired 2,225 shares of Immix Biopharma Common Stock through a purchase (P) transaction.
• The shares were purchased at a volume-weighted average price of $2.279 per share.
• Following this transaction, Mr. Morris directly beneficially owns 288,059 shares of Common Stock.
• Additionally, he indirectly beneficially owns 270,844 shares through Alwaysraise LLC and 24,141 shares through Alwaysraise Ventures I, LP, though he disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The purchase of shares by a key insider (CFO and Director) generally indicates confidence in the company's future performance, which is a positive signal for investors.

Positives

• A key insider, the CFO and Director, purchased additional shares, which typically signals confidence in the company's future performance and valuation.
• The transaction increases the direct beneficial ownership of a senior executive in the company, aligning management's interests further with shareholders.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the insider purchase as a positive signal of management's confidence in the company's prospects and valuation, potentially influencing investor sentiment.

Key Dates

Recommendation

Keywords

Immix Biopharma, IMMX, Gabriel Morris, CFO, Director, Insider Trading, Stock Purchase, Beneficial Ownership, SEC Form 4, Biopharma